Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cancer sniffing dogs to aid British doctors

They’re known as man’s best friend; but dogs could soon also be their greatest ally in the fight against prostate cancer. Britain’s National Health Service recently approved a trial for dogs capable of sniffing out prostate cancer in the hope that it could show up inaccuracies in the current PSA (prostate specific antigen) test. It’s […]

Read More »

Novo to begin Phase III trial of oral diabetes treatment

Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after “encouraging” results in previous trials. The tests are for what is calls a long-acting GLP-1 analogue semaglutide. The oral tablet is a part of Novo Nordisk’s effort to […]

Read More »

Sucampo Offers to Buy R-Tech Ueno for $278 Million

Sucampo Launches Tender Offer to Acquire R-Tech Ueno Acquisition Expected to be Immediately Accretive Advances Sucampo Strategy to Strengthen Financial Performance and Diversify Pipeline Acquisition Expected to Close in Q4 2015 Company to Host Conference Call Today at 8:00 a.m. EDT   BETHESDA, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today […]

Read More »

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

TUEBINGEN, Germany and HOUSTON, Aug. 26, 2015 /PRNewswire/ — Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types. Immatics believes that ACT […]

Read More »

Medtronic Jumps Into Mitral Valve Race with $458 Million Deal for Twelve Inc.

Medtronic To Acquire Twelve, Developer Of Transcatheter Mitral Valve Replacement Device DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on […]

Read More »

Lilly Says Court Ruled in its Favor on Patent

Eli Lilly & Co. said a federal court ruled that generic products proposed by a Teva Pharmaceutical Industries Ltd. TEVA -0.43 % unit would infringe a U.S. patent for the drug maker’s blockbuster cancer drug Alimta. A Teva spokesman said “we are disappointed with the district court’s decision and we are evaluating our options to […]

Read More »

FDA Grants Priority Review to Sarepta Drug

U.S. health regulators granted priority review status for Sarepta Therapeutics Inc. SRPT -0.91 % ’s treatment of a rare genetic disorder. Sarepta is developing eteplirsen to treat Duchenne muscular dystrophy, a condition that destroys muscles and frequently kills patients by their 30s. The disease affects roughly one in every 3,500 boys world-wide. The Food and […]

Read More »

BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis

FRANKLIN LAKES, N.J., Aug. 25, 2015 /PRNewswire/ — BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc. BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years […]

Read More »

Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceedings against Two Copaxone® 40 mg/mL Dosing Patents

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ — Mylan N.V. (Nasdaq: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has instituted inter partes review (IPR) proceedings against two Copaxone® 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries […]

Read More »

Mylan Launches Generic Zosyn Injection

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ — Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer’s Zosyn® Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom